American States Water Company vs ClearPoint Neuro Inc — how do they compare? American States Water Company trades at $87.85 (market cap $3.47B), while ClearPoint Neuro Inc trades at $15.2 (market cap $454.21M). The key difference: American States Water Company is far larger — about 7.6× ClearPoint Neuro Inc's market cap, and American States Water Company pays a 2.49% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| AWR | CLPT | |
|---|---|---|
Market Cap | $3.47B | $454.21M |
Sector | Utilities | Health |
52-Week High | $89.28 | $29.60 |
52-Week Low | $70.10 | $8.66 |
Enterprise Value | $4.37B | $488.79M |
Dividend Yield | 2.49% | — |
Signals from Pluang's Aura AI — not financial advice
AWR trades at $87.95, up 1.59% on the day, with a bullish technical signal from moving averages. The company reported a Q2 2026 EPS beat of $1.09 versus $0.915 expected, driven by water rate increases and revenue growth. Recent news highlights its 71-year dividend growth streak and an 8.2% dividend hike announced in July 2026. Financials show solid profitability with a 20.52% net income margin and ROE of 13.62%, though valuation ratios like P/E of 23.92 are above sector averages.
Outlook is mixed: strong dividend history and earnings growth support income investors, but elevated valuation and mixed analyst consensus (20% buy, 50% hold, 30% sell) suggest limited near-term upside. Key risks include regulatory dependence on rate approvals and potential overvaluation relative to peers.
ClearPoint Neuro (CLPT) trades at $15.18, up 4.19% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue growth but missed earnings expectations with a $0.38 loss per share. Despite negative profitability metrics, analyst consensus remains unanimously bullish with 100% buy ratings. Recent news highlights regulatory progress with partners and expansion of the drug delivery ecosystem.
The stock presents a high-risk opportunity with strong analyst support despite current losses. Investment thesis hinges on successful commercialization of neuro drug delivery technologies and partnership execution. Key risks include persistent negative cash flow from operations and delayed revenue ramp-up from new facilities. Upside depends on translating regulatory momentum into sustainable revenue growth.
Trailing returns across standard periods
Latest headlines on both assets
American States Water provides water and electric services to over one million people in the U.S. It also manages water and wastewater systems for various military bases under long-term privatization contracts.
Read more on AWR →ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →